Similar findings were observed by Riaz et al. (GSE91061)23 in melanoma and non‐small cell lung cancer cohorts, where patients with complete or partial remission showed lower FOXK2 expression compared to those with disease stabilization or progression after immunotherapy (Figure 4c,d). The gene discussed is FOXK2; the disease is lung cancer.